Effects of oral glibenclamide on reduction of size of brain contusions and peri contusional edema and prognosis of patients with moderate and severe traumatic brain injury: a randomized clinical trial

Vice Chancellor of Research, Shiraz University of Medical Sciences0 个研究点目标入组 104 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Documented closed head injury; Age between 18 and 75 years; Having brain contusions on initial brain CT scan; Taking the first dosage of medication within first 10 hours of trauma event; GCS:5-13 without influence of sedations upon admission; Obtaining written informed consent from legally authorized representative
•Exclusion criteria: Having a lesion on brain CT which urges a surgical evacuation at any time of hospital admission (Surgical EDH, SDH, ICH or midline shift>5mm and decompressive craniectomy); Spinal cord injury or spinal column instability with neurologic deficit; Penetrating brain injury; Any blood glucose under 50mg/dL or over 500mg/d; Severe renal disorder from past history or Cr>2.5 or patients on hemodialysis; Severe liver disease from past history or total bilirubin above 1.5 times of normal value; INR>1.6; Systolic BP below 90mmHg on admission without respond to fluid resuscitation; Pregnant women or a positive pregnancy test or those who intend to breastfeed during study days; Associated severe non-survivable injury; History of previous brain problems (Tumor, infections, strokes, …); Usage of warfarin, heparin, clopidogrel, LMWH within 72 hours prior to traumatic event

发起方

Vice Chancellor of Research, Shiraz University of Medical Sciences